this from NSTK's release below makes interesting reading but is not a threat yet to PTIE's efforts.
" Advanced the <<preclinical program>> and regulatory strategy of CC-109, a novel, proprietary class of orally-administered opioid analgesics designed to combine the desirable slow release kinetics of 'physical' formulations like OxyContin(R), a branded controlled-release narcotic painkiller with annual sales exceeding $1.5 billion, with the security of a chemically-modified opioid, that cannot be abused by simply crushing a tablet or dissolving a sticky, high-viscosity formulation, but releases opioids by the actions of normal enzymes found in the body."
Thanks for not mentioning my typo on "here." After rereading my message, I was thinking you might be questioning my UVA education.
I recently rented a condo in Charlottesville as a getaway and chance to renew my acquaintance with Virginia.
It's still sitting empty right on the downtown square. Maybe I'll use it some day.
Congratulations on the 79. I need to play more golf.
Awonabee...I own both NSTK and PTIE and this is the one complaint I have about Remi. He may have a great stable of drugs, but he can only prove it by doing a deal. The NSTK drug is going to accellerated as are other compounds at other drug and biotech companies. I think the longer Remi waits the market is going to feel he can't make a deal and the large drug companies have no interest. With the Phase II Oxytrex data the stock languishes.
The great arbiter of value is the market, and unless I am missing something, the market may be having a tough time believing the company's story line. I am willing to give my investment time, but I do not think that is a luxury Remi and the company have. All you need is a major announcement by a big drug operation that they have a great non-addictive oxycontin type drug.
The risk of hubris and ego.
I think the market's focus may have shifted to eventualities elsewhere.
Managed to sell half my holding above $6.00 today.
Nice at NSTK today !!! well done, don't own it but tempted by their PYY candidate.
I fear the widespread sell-off may continue into next week. We'v ranged from being over sold back in Feb/Mar to over bought in Aug/Sep. There is now a chance we may well see the othe end of the pendulum yet again. Especially for companies without earnings support.
Look at this new director. He lives in Lake Forest, IL.
He has impeccable credentials.
And he doesn't agree with you.
PTI has retained worldwide rights so that we can all make a 1000% over the next few years.
The best for PTI obviuosly if remoxy succeed and this competitor fails.
On the other hand it is not that bad for PTI if that succeeds only. They would need to partnet with to bring the nonabusable version oxytrex to market.
Worst possibility is if all such effort fails.